One market in particular is too lucrative for it to miss out on any longer.Despite its impressive performance in 2020 and 2021, it's no secret that Pfizer (PFE 3.39%) is in the process of reinventing itself. Without much of the windfall from its coronavirus products propping up the top line, it may be years until revenue can top its recent peak.But that just means the company has an incentive to make big plays and take big risks to delight its shareholders. On that front, here's my prediction for what its n ...

georgeclerkIn this article, I will outline why I think the high yielding pharmaceutical giant Pfizer (NYSE:PFE) looks bullish. Pfizer, known for Eliquis and Xeljanz, yields 5.57% and has a dividend safety rating of B- according to Seeking Alpha. I will outline my investment thesis using technical analysis tools such as price action, volume, momentum, and relative strength. I last wrote about PFE being bullish back in April 2021. Pfizer has since risen and then sold off considerably, so now I will take a ...

Pfizer logo is seen on Pfizer World Headquarters in Manhattan, New York, United States of America, ... [+] on July 6th, 2024. (Photo by Beata Zawrzel/NurPhoto via Getty Images)NurPhoto via Getty ImagesPfizer (NYSE: PFE) is scheduled to report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $12.95 billion and earnings of $0.44 on a per share and adjusted basis, lower than the consensus estimates. The company is likely to see higher sales, led by an uptick in Eliquis and Prev ...

Wall Street analysts expect Pfizer (PFE) to post quarterly earnings of $0.45 per share in its upcoming report, which indicates a year-over-year decline of 32.8%. Revenues are expected to be $13.13 billion, up 3.1% from the year-ago quarter.The current level reflects an upward revision of 0.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Before a company revea ...

Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.At last check Wednesday, Sangamo was up more than 36.2%, trading at 55 cents per share.Both companies released results from the Phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for adult patients with moderately severe to severe hemophilia A.The AFFINE study achieved its primary objective.Also Read: Sec ...

Pfizer (PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share, respectively. Earnings estimates for Pfizer have risen from $2.38 to $2.39 per share over the past seven days. For 2025, earnings estimates have been stable at $2.75 per share over the same timeframe.Image Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been solid, ...

With danuglipron, Pfizer could become a major player in the massive GLP-1 agonist market.If there's one thing healthcare giant Pfizer (PFE -0.12%) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are unsure about how strong its long-term prospects are, which explains why the stock is in such a slump -- down more than 25% in three years.But sometimes all it takes is one successful product to turn a company's fortunes aro ...

Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval.The treatment for hemophilia A could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for a less common type of the bleeding disorder called hemophilia B. Pfizer is co-developing the therapy with Sangamo Therapeutics, whose shares rose more than 60% on Wednesday following the ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other ...

Neither is a leader right now, but one of them might be on track to change that.Both Pfizer (PFE 0.88%) and Roche Holdings (RHHBY -0.18%) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes of Novo Nordisk and Eli Lilly.Still, both have ongoing plans to develop weight loss pills. If those plans pan out, the returns are likely to be enormous. So which of these dark ...